HC Wainwright Predicts Valneva's Q1 Earnings (NASDAQ:VALN)

Valneva SE (NASDAQ:VALN - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Valneva in a research note issued to investors on Thursday, January 23rd. HC Wainwright analyst E. White forecasts that the company will post earnings of ($0.38) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Valneva's current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Valneva's Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS and Q4 2025 earnings at ($0.31) EPS.

Valneva Price Performance

VALN traded up $0.16 during midday trading on Friday, reaching $4.90. 54,197 shares of the company's stock were exchanged, compared to its average volume of 44,826. The business's 50-day moving average price is $4.28 and its 200 day moving average price is $5.80. The stock has a market capitalization of $398.17 million, a PE ratio of -37.69 and a beta of 1.93. Valneva has a 1-year low of $3.62 and a 1-year high of $9.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25.

Hedge Funds Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC increased its stake in shares of Valneva SE (NASDAQ:VALN - Free Report) by 33.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 118,000 shares of the company's stock after purchasing an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 as of its most recent filing with the Securities and Exchange Commission. 11.39% of the stock is currently owned by institutional investors and hedge funds.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.